S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.55 (+2.10%)
AAPL   160.50 (+1.69%)
MSFT   280.29 (+2.94%)
META   206.14 (+3.17%)
GOOGL   105.93 (+2.48%)
AMZN   100.22 (+1.54%)
TSLA   195.34 (+2.19%)
NVDA   273.48 (+3.32%)
NIO   9.30 (+2.31%)
BABA   86.79 (+3.75%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.66 (+1.57%)
MU   61.10 (+5.04%)
CGC   1.90 (+1.29%)
GE   92.15 (+2.86%)
DIS   96.64 (+1.83%)
AMC   4.55 (+4.84%)
PFE   40.44 (+1.07%)
PYPL   73.39 (-1.28%)
NFLX   319.42 (+8.68%)
S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.55 (+2.10%)
AAPL   160.50 (+1.69%)
MSFT   280.29 (+2.94%)
META   206.14 (+3.17%)
GOOGL   105.93 (+2.48%)
AMZN   100.22 (+1.54%)
TSLA   195.34 (+2.19%)
NVDA   273.48 (+3.32%)
NIO   9.30 (+2.31%)
BABA   86.79 (+3.75%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.66 (+1.57%)
MU   61.10 (+5.04%)
CGC   1.90 (+1.29%)
GE   92.15 (+2.86%)
DIS   96.64 (+1.83%)
AMC   4.55 (+4.84%)
PFE   40.44 (+1.07%)
PYPL   73.39 (-1.28%)
NFLX   319.42 (+8.68%)
S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.55 (+2.10%)
AAPL   160.50 (+1.69%)
MSFT   280.29 (+2.94%)
META   206.14 (+3.17%)
GOOGL   105.93 (+2.48%)
AMZN   100.22 (+1.54%)
TSLA   195.34 (+2.19%)
NVDA   273.48 (+3.32%)
NIO   9.30 (+2.31%)
BABA   86.79 (+3.75%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.66 (+1.57%)
MU   61.10 (+5.04%)
CGC   1.90 (+1.29%)
GE   92.15 (+2.86%)
DIS   96.64 (+1.83%)
AMC   4.55 (+4.84%)
PFE   40.44 (+1.07%)
PYPL   73.39 (-1.28%)
NFLX   319.42 (+8.68%)
S&P 500   3,981.67 (+1.14%)
DOW   32,318.92 (+0.90%)
QQQ   312.55 (+2.10%)
AAPL   160.50 (+1.69%)
MSFT   280.29 (+2.94%)
META   206.14 (+3.17%)
GOOGL   105.93 (+2.48%)
AMZN   100.22 (+1.54%)
TSLA   195.34 (+2.19%)
NVDA   273.48 (+3.32%)
NIO   9.30 (+2.31%)
BABA   86.79 (+3.75%)
AMD   101.60 (+4.12%)
T   18.52 (+0.71%)
F   11.66 (+1.57%)
MU   61.10 (+5.04%)
CGC   1.90 (+1.29%)
GE   92.15 (+2.86%)
DIS   96.64 (+1.83%)
AMC   4.55 (+4.84%)
PFE   40.44 (+1.07%)
PYPL   73.39 (-1.28%)
NFLX   319.42 (+8.68%)
NASDAQ:IOBT

IO Biotech - IOBT Competitors

$2.02
-0.03 (-1.46%)
(As of 03/23/2023 12:42 PM ET)
Add
Compare
Today's Range
$2.02
$2.15
50-Day Range
$1.98
$2.98
52-Week Range
$1.91
$9.77
Volume
8,247 shs
Average Volume
77,324 shs
Market Capitalization
$39.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

IOBT vs. ABEO, ONCT, GNPX, TNXP, LVTX, MBIO, ALZN, DMAC, ASLN, and MDNA

Should you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Abeona Therapeutics (ABEO), Oncternal Therapeutics (ONCT), Genprex (GNPX), Tonix Pharmaceuticals (TNXP), LAVA Therapeutics (LVTX), Mustang Bio (MBIO), Alzamend Neuro (ALZN), DiaMedica Therapeutics (DMAC), ASLAN Pharmaceuticals (ASLN), and Medicenna Therapeutics (MDNA). These companies are all part of the "pharmaceutical preparations" industry.

IO Biotech vs.

IO Biotech (NASDAQ:IOBT) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking.

IO Biotech has a beta of -0.61, indicating that its share price is 161% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

In the previous week, IO Biotech had 11 more articles in the media than Abeona Therapeutics. MarketBeat recorded 17 mentions for IO Biotech and 6 mentions for Abeona Therapeutics. IO Biotech's average media sentiment score of 0.73 beat Abeona Therapeutics' score of 0.14 indicating that IO Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IO Biotech
0 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abeona Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

53.2% of IO Biotech shares are held by institutional investors. Comparatively, 37.7% of Abeona Therapeutics shares are held by institutional investors. 11.6% of IO Biotech shares are held by insiders. Comparatively, 2.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IO Biotech's return on equity of -43.58% beat Abeona Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
IO Biotech N/A -43.58% -41.05%
Abeona Therapeutics N/A -157.61% -85.45%

Abeona Therapeutics received 503 more outperform votes than IO Biotech when rated by MarketBeat users. However, 88.89% of users gave IO Biotech an outperform vote while only 71.27% of users gave Abeona Therapeutics an outperform vote.

CompanyUnderperformOutperform
IO BiotechOutperform Votes
8
88.89%
Underperform Votes
1
11.11%
Abeona TherapeuticsOutperform Votes
511
71.27%
Underperform Votes
206
28.73%

IO Biotech currently has a consensus target price of $10.50, suggesting a potential upside of 412.20%. Abeona Therapeutics has a consensus target price of $40.00, suggesting a potential upside of 1,566.67%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than IO Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IO Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Abeona Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

IO Biotech has higher earnings, but lower revenue than Abeona Therapeutics. IO Biotech is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IO BiotechN/AN/A-$71.46 million-$2.49-0.82
Abeona Therapeutics$3 million13.74-$84.94 million-$18.31-0.13

Summary

IO Biotech beats Abeona Therapeutics on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IOBT vs. The Competition

MetricIO BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$39.05M$5.51B$4.33B$5.81B
Dividend YieldN/A2.60%2.39%4.45%
P/E Ratio-0.823.7895.6311.70
Price / SalesN/A294.983,598.8157.70
Price / CashN/A19.3326.8498.19
Price / Book0.434.134.464.94
Net Income-$71.46M$187.59M$115.42M$190.83M
7 Day Performance-6.82%-3.81%-2.47%-1.39%
1 Month Performance-19.92%-10.67%-6.55%-6.86%
1 Year Performance-60.42%-14.85%-16.10%-18.39%

IO Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABEO
Abeona Therapeutics
2.2371 of 5 stars
$2.40
-2.0%
$22.00
+816.7%
-68.1%$41.23M$3M-0.13N/AUpcoming Earnings
ONCT
Oncternal Therapeutics
2.2936 of 5 stars
$0.71
+11.0%
$6.67
+844.2%
-53.8%$41.46M$1.49M-0.8426Analyst Report
GNPX
Genprex
2.0715 of 5 stars
$0.81
+2.5%
$3.00
+270.2%
-65.9%$39.04MN/A-1.6912Upcoming Earnings
Gap Up
TNXP
Tonix Pharmaceuticals
2.1974 of 5 stars
$0.62
+5.1%
$12.85
+1,972.6%
-92.3%$38.78MN/A-0.1573News Coverage
LVTX
LAVA Therapeutics
1.7624 of 5 stars
$1.64
-3.0%
$14.33
+774.0%
-65.1%$42.08M$5M-1.5555Gap Up
MBIO
Mustang Bio
1.8379 of 5 stars
$0.37
-2.7%
$4.75
+1,200.7%
-64.5%$38.74MN/A-0.46102
ALZN
Alzamend Neuro
1.1816 of 5 stars
$0.44
+4.8%
N/A-67.1%$42.14MN/A0.003News Coverage
Gap Up
High Trading Volume
DMAC
DiaMedica Therapeutics
1.9672 of 5 stars
$1.60
-7.0%
$10.00
+525.0%
-46.3%$42.30MN/A-3.3314Upcoming Earnings
Gap Down
ASLN
ASLAN Pharmaceuticals
1.7543 of 5 stars
$2.75
-6.1%
$18.75
+581.8%
-36.0%$38.36MN/A-0.7918Upcoming Earnings
Stock Split
Analyst Revision
News Coverage
MDNA
Medicenna Therapeutics
1.9643 of 5 stars
$0.55
-1.8%
$2.50
+354.5%
-59.3%$38.30MN/A-4.2313Negative News
Gap Down
This page (NASDAQ:IOBT) was last updated on 3/23/2023 by MarketBeat.com Staff